Abstract

The purpose of this rapid review is to identify and evaluate the evidence proposing sodium thiosulfate as a preventive agent for the ototoxic effects of cisplatin-based chemotherapy treatments.

Methods: A literature database search analysis was completed by using PUBMED, CINAHL, and Embase. Using the PICO framework, search criteria included hearing loss and sodium thiosulfate prevention methods. There was no discrimination on age for this review.

Results: Four articles were chosen to be analyzed in this rapid review. This includes 3 randomized control trials and 1 cohort study. Each of these studies evaluated sodium thiosulfate being administered simultaneously to prevent cisplatin-induced hearing loss.

Conclusion: Hearing loss is common in cisplatin-based chemotherapies. Sodium thiosulfate has been found to slightly reduce the impact on cisplatin-induced hearing loss. Sodium thiosulfate does not exacerbate other symptoms of cancer or cisplatin.